Prediction of blood culture results by measuring procalcitonin levels and other inflammatory biomarkers - 29/03/14
, Kenichiro Kumasaka, MD, Katuhiro Nagata, MD, Taihei Okita, MD, Taishi Oomura, MD, Akira Hoshiai, MD, Masaharu Koyama, PhD, Shoichi Ohta, MD, PhD, Tetsuo Yukioka, MD, PhDAbstract |
Background |
It would be helpful if we could predict positive or negative blood culture results. This study considered the usefulness of measuring procalcitonin (PCT) level and standard clinical biomarkers such as white blood cell (WBC) count, C-reactive protein (CRP) level, and platelet (PLT) count to predict blood culture results.
Method |
We retrospectively analyzed the data from 422 specimens collected at our emergency center within the preceding 36 consecutive months. Primary component analysis (PCA) was used for detecting the degree of the relational contribution of each of the 4 biomarkers to the blood culture results.
Results |
Procalcitonin alone (cut-off value, 0.5 ng/mL) yielded a positive blood culture rate of 34.0%. Procalcitonin plus 3 biomarkers (WBC, CRP, and PLT) analyzed by PCA yielded 45.9% or 35.3% when a case was in the first or fourth quadrant, which was significantly higher than cases in the second or third quadrant. Primary component analysis also revealed that positive blood culture results were mainly affected by primary component 1, to which PCT and PLT (not WBC or CRP) predominantly contribute.
Conclusion |
Although it is difficult to predict blood culture results, even using 4 biomarkers analyzed by PCA, our new finding that blood culture results are affected not by WBC and CRP, but mainly by PCT and PLT, might help explain the mechanism of sepsis.
Le texte complet de cet article est disponible en PDF.Plan
Vol 32 - N° 4
P. 330-333 - avril 2014 Retour au numéro
Article précédent
- Traditional nurse triage vs physician telepresence in a pediatric ED
- Greg P. Marconi, Todd Chang, Phung K. Pham, Daniel N. Grajower, Alan L. Nager
- Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial
- Francesco Travaglino, Veronica Russo, Benedetta De Berardinis, Filippo Numeroso, Pamela Catania, Gianfranco Cervellin, Stefano Geniere Nigra, Francesco Geraci, Maria Antonietta Bressan, Stefania Guerrini, Mario Cavazza, Christian Folli, Valter Monzani, Stefania Battista, Giulio Mengozzi, Paola Noto, Giuseppe Carpinteri, Andrea Semplicini, Federica Stella, Stella Ingrassia, Paolo Moscatelli, Patrizia Giuntini, Gerardo Salerno, Patrizia Cardelli, Salvatore Di Somma
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?